Skip to main content

A case of primary aldosteronism with a negative aldosterone-to-renin ratio

Abstract

Background

Primary aldosteronism (PA), as a cause of secondary hypertension, can cause more serious cardiovascular damage than essential hypertension. The aldosterone-to-renin ratio (ARR) is recommended as the most reliable screening method for PA, but ARR screening is often influenced by many factors. PA cannot be easily excluded when negative ARR.

Case presentation

We report the case of a 45-year-old Chinese man with resistant hypertension. Three years ago, he underwent a comprehensive screening for secondary hypertension, including the ARR, and the result was negative. After that, the patient's blood pressure was still poorly controlled with four kinds of antihypertensive drugs, the target organ damage of hypertension progressed, and hypokalaemia was difficult to correct. When the patient was hospitalized again for comprehensive examination, we found that aldosterone levels had significantly increased, although the ARR was negative. An inhibitory test with saline was further carried out, and the results suggested that aldosterone was not inhibited; therefore, PA was diagnosed. We performed a unilateral adenoma resection for this patient, and spironolactone was continued to control blood pressure. After the operation, blood pressure is well controlled, and hypokalaemia is corrected.

Conclusion

When the ARR is negative, PA cannot be easily excluded. Comprehensive analysis and diagnosis should be based on the medication and clinical conditions of patients.

Peer Review reports

Background

Primary aldosteronism (PA), as a cause of secondary hypertension, was originally defined and reported by Conn [1]. PA refers to the autonomic secretion of aldosterone in the adrenal cortex, resulting in potassium excretion and increased blood volume in vivo and the inhibition of the activity of the renin angiotensin system. Compared with patients with essential hypertension, the damage to target organs, such as the heart and kidney, in patients with PA is more serious [2, 3]. Therefore, early screening of PA in patients with hypertension is very important.

In PA, a high aldosterone concentration is accompanied by a low level of renin because the negative feedback circuit inhibits the secretion of renin. During the development of PA from the normal renin and aldosterone values of healthy individuals to explicit PA, aldosterone is significantly increased, renin is completely inhibited (which is a continuous process), and the aldosterone-to-renin ratio (ARR) continues to rise [4]. The ARR, first proposed by Hiramatsu et al [5], is recommended as the most reliable screening method for PA. If the ARR is positive, further confirmatory tests should be performed; if it is negative, PA screening can be stopped [6, 7]. ARR screening is often influenced by many factors, such as sex, hypokalaemia, body position, measurement time, salt intake, antihypertensive drugs, renal function and age [4]. In clinical diagnosis, we should combine the ARR and clinical manifestations and laboratory examination results to avoid missed diagnosis of PA. We report a case of PA with a negative ARR.

Case presentation

A 45-year-old Chinese man had elevated blood pressure for 4 years, and the highest blood pressure was 200/130 mmHg. In 2017, he was hospitalized in our department for adrenal Computed tomography (CT) examination, in which a left adrenal nodule was observed, and ARR screening for PA was negative, with an aldosterone/renin ratio of 0.91 (according to the guideline [6], aldosterone (ng/dl), direct renin concentration (ng/l), and the ARR cut-off point were 3.8, 5.7 and 7.7, respectively) (Table 3). Secondary hypertension was ruled out by laboratory and imaging examinations. The final diagnosis was essential hypertension. He had a history of smoking for 20 years and denied any remarkable family medical history. Many times blood potassium was lower than normal. Nifedipine controlled-release tablets, perindopril and indapamide tablets, metoprolol sustained-release tablets and spironolactone were all used to control blood pressure, but the blood pressure was still poorly controlled, and the antihypertensive drugs were adjusted many times. The patient had occasional dizziness and palpitations, but no chest tightness, no chest pain, no syncope, and no weakness. The patient came to our hospital again due to poor blood pressure control. After 2 weeks of oral administration of nifedipine controlled-release tablets combined with doxazosin, the patient was rehospitalized for further thorough examination.

Physical examination results were as follows: pulse, 64 times/min; blood pressure, 165/108 mmHg; body mass index, 25.88 kg/m2; heart murmur boundary enlarged to the left; and no other abnormalities. Auxiliary examination results were as follows: the results of routine blood, routine blood coagulation, liver function and thyroid function tests were all normal, as were D-dimer, blood glucose and glycosylated haemoglobin levels. The rhythm of cortisol was normal. The results of the two examinations (in 2017 and 2020) were all abnormal: hypokalaemia, mild renal dysfunction, and positive urine protein (Table 1). In 2017, when the synchronous blood electrolytes were 3.32 mmol/l, the 24-h urine potassium was 32.94 mmol, suggesting increased potassium in urine. In other imaging examinations (Table 2), left ventricular hypertrophy was indicated by cardiac colour Doppler ultrasonography, and the ventricle presented hypertrophic enlargement compared with 2017; carotid artery colour Doppler ultrasonography indicated carotid atherosclerosis, which also indicated the progression of atherosclerosis; renal artery colour Doppler ultrasonography showed no abnormality. CT of the adrenal gland showed that the adrenal glands were both thickened, and multiple round soft-tissue density shadows, such as soft tissue density shadows, could be seen in both adrenal glands. The larger one was located in the left inner branch of the adrenal gland, with a diameter of 8 mm (Fig. 1).

Table 1 Biochemical examination results
Table 2 Auxiliary examination results
Fig. 1
figure1

Adrenal computed tomography (CT) scan. The arrows indicate the adenoma

In 2020, the patient again underwent a postural test (Table 3). Although the ARR was negative (aldosterone/renin was 0.57), the level of aldosterone had increased significantly (> 20 ng/dl), indicating that the inappropriate secretion of aldosterone had increased. Based on this evidence, an inhibitory test with saline (infusion of 2 l of saline within 4 h) was further carried out. As shown in Table 4, aldosterone was more than 10 ng/dl after saline treatment, suggesting that aldosterone was not inhibited. We summarized the clinical features of this patient as follows: hypertension combined with hypokalaemia, poor blood pressure control by various antihypertensive drugs, significant progress of target organ damage of hypertension, increased basal aldosterone levels (> 20 ng/dl), aldosterone not inhibited after saline treatment (> 10 ng/dl), and a diagnosis of PA.

Table 3 Positional test
Table 4 the inhibitory test with saline

For the bilateral adrenal multiple adenomas, we further performed bilateral adrenal venous sampling (AVS). For hormonal examination, blood specimens were collected from 4 different sites, including the left adrenal vein, right adrenal vein, postcava and precava. The test results are shown in Table 5. The selectivity index of right and left adrenal venous cannulation was 2.9 and 2.22 (Table 5), respectively, and judged as successful [2]. When we compared the ratio of aldosterone-over-cortisol (A/C) obtained in both adrenal veins, the lateralization index was 1.01 (< 2) (Table 5), indicating no dominant secretion [8]. Because AVS showed no dominant secretion of either adrenal gland, it was recommended that the patient take oral medication to control hypertension. We considered that bilateral adrenal adenomas were functional, and the patient had poor blood pressure control with a variety of antihypertensive drugs in the past, serious target organ damage, and hypokalaemia that was difficult to correct. On the basis of the evidence, after obtaining the consent of the patient, the patient was transferred to the urology department for laparoscopic resection of the left large adrenal adenoma. Postoperative pathology was indicative of adrenal adenoma (Fig. 2). Postoperative blood potassium was 4.12 mmol/l. After the operation, the blood pressure of the patient was more easily controlled than before. After 6 months, blood pressure was controlled at 130/90 mmHg with three kinds of antihypertensive drugs (nifedipine controlled-release tablets, arotinolol, spironolactone).

Table 5 Adrenal vein blood sampling
Fig. 2
figure2

Pathological picture of left adrenal adenoma

Discussion and conclusions

We reported a case of primary aldosteronism. Although the initial screening test (ARR) was negative, we further confirmed the diagnosis with the inhibitory test with saline and concluded that PA could not be excluded when ARR was negative. According to the guidelines [6], PA can be diagnosed by a positive orthostatic ARR and confirmatory tests, but many factors affect the results of PA screening and confirmatory tests. As a clinical disease, the diagnosis of PA should be based on complete clinical manifestations, laboratory examination, AVS, histopathology and treatment response.

Aldosterone is a hormone regulating blood volume in the human body which regulated by renin-angiotensin system (RAS), angiotensin II, adrenocorticotropic hormone(ACTH) and potassium ions. In PA, the relative high blood volume caused by increased aldosterone further inhibits RAS; aldosterone secretion is relatively independent of the inhibited RAS, but can be affected by body position, hormone [9] and various receptor ligands [10], which may lead to great variability of aldosterone levels in PA patients. It has been reported that chronic stress induced by ACTH leads to ACTH dependent hyperaldosterone secretion in hypertensive patients without PA [11]. When hypokalemia and resistant hypertension exist, the possibility of PA is very high. In the case of low renin level, the production of aldosterone at any level suggests that there may be potential PA. Two studies have shown that even normal aldosterone levels(< 10 ng/dl) may be an indicator of PA [12, 13]. Oelkers et al. [14] reported three patients with PA complicated by renal insufficiency whose plasma renin was not inhibited. In these patients, plasma renin activity was in the normal/high normal range, which may have been related to renal vascular injury leading to glomerular ischaemia and renin escaping excess aldosterone inhibition. In the diagnosis of PA with the ARR, the effect of renal damage on plasma renin concentration (PRC) may cause an increase in the PRC, which leads to a false lower ARR value, thus masking PA [15].

This patient had mild renal insufficiency, which may have been a cause of the negative ARR. There are different reports on the ARR cut-off point in the diagnosis of PA in domestic and foreign studies [4]. At present, the ARR cut-off point recommended by previous studies is used in the screening of PA in patients with hypertension, and whether this cut-off point is in line with the local population has not been further discussed; therefore, PA may be missed in some people with an ARR lower than the cut-off point. In 2017, Zorzl et al [16] reported a 27-year-old patient with hypertension who was diagnosed with essential hypertension after a negative ARR was determined. Many years later, the patient repeatedly went to the hospital due to poor blood pressure control (taking four kinds of antihypertensive drugs at the same time) and hypokalaemia. After 14 years, the ARR was positive, and PA was confirmed by the inhibitory test with saline and AVS. After the operation, blood pressure and potassium levels returned to normal. Therefore, when the ARR is negative, PA cannot be easily excluded. Comprehensive analysis and diagnosis should be based on the medication and clinical conditions of patients.

Bilateral adrenal diseases can be divided into three types: idiopathic adrenal hyperplasia (IAH), bilateral aldosterone-producing adenoma (APA) and glucocorticoid-remediable aldosteronism (GRA) [6]. It is difficult to distinguish bilateral APA from IAH even with successful AVS [17]. In 2016, Japanese scholars used segmental AVS (S-AVS) to confirm that the veins in the tumour segment secreted too much aldosterone and inhibited the bilateral secretion of veins in the nontumour segment, leading to the diagnosis of bilateral APA [17]. In theory, bilateral APA can also be cured by surgery, but there are few successful cases reported in the literature. Few patients with bilateral APA underwent surgery and were cured by surgery [17,18,19,20].

Guidelines recommend mineralocorticoid receptor (MR) antagonists for PA patients with bilateral adrenal disease [6]. However, it has been reported that the cardiovascular risk of PA patients is higher than that of patients with essential hypertension, despite good blood pressure control [21]. When MR antagonists are used, the decline in glomerular filtration rate increases the risk of hyperkalaemia, and large doses of MR antagonists, which can block MR sufficiently, are also limited [22]. The use of high-dose spironolactone also has anti-androgen side effects. A Japanese national survey also showed that surgical treatment can improve hypertension and hypokalaemia in unilateral and bilateral adrenal lesions [23]. Scholars have raised the following question: Can adrenalectomy reduce aldosterone exposure in PA patients with bilateral adrenal diseases? [24] There is a lack of effective clinical research to answer this question, and more prospective studies are needed. For PA patients whose blood pressure cannot be controlled sufficiently or whose hypokalaemia is difficult to correct or whose renal function is impaired and the dosage of MR antagonist cannot be increased to the maximum, scholars propose the choice of unilateral adrenalectomy to reduce the severity of the disease, coupled with long-term MR antagonist treatment [24]. We performed a unilateral adenoma resection for this patient, who continued taking spironolactone to control blood pressure. Currently, blood pressure is well controlled, and good clinical effects have been achieved.

Finally, we summarize some experience gained from this case and some hints for future clinical work. Clinically, for patients with atypical suspected PA, we should not rely only on hormone level and ARR screening to exclude PA, but we should make a judgement after comprehensive evaluation of clinical manifestations and laboratory and imaging examinations. For PA patients, long-term clinical follow-up observation, including the monitoring of drug side effects, blood pressure and various cardiovascular complications, is also needed, regardless of the choice of drugs or surgical treatment.

Availability of data and materials

All relevant data supporting the conclusions of this article are included within the article.

Abbreviations

PA:

Primary aldosteronism

ARR:

Aldosterone-to-renin ratio

CT:

Computed tomography

AVS:

Adrenal venous sampling

S-AVS:

Segmental AVS

PRC:

Plasma renin concentration

IAH:

Idiopathic adrenal hyperplasia

APA:

Aldosterone-producing adenoma

GRA:

Glucocorticoid-remediable aldosteronism

MR:

Mineralocorticoid receptor

A:

Aldosterone

C:

Cortisol

A/C:

A ratio of aldosterone-over-cortisol

SI:

Selectivity index

References

  1. 1.

    Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45(1):3–17.

    CAS  Google Scholar 

  2. 2.

    Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62(2):331–6.

    CAS  Article  Google Scholar 

  3. 3.

    Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98(12):4826–33.

    CAS  Article  Google Scholar 

  4. 4.

    Schilbach K, Junnila RK, Bidlingmaier M. Aldosterone to renin ratio as screening tool in primary aldosteronism. Exp Clin Endocrinol Diabetes. 2019;127(2–03):84–92.

    CAS  PubMed  Google Scholar 

  5. 5.

    Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med. 1981;141(12):1589–93.

    CAS  Article  Google Scholar 

  6. 6.

    Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916.

    CAS  Article  Google Scholar 

  7. 7.

    Mulatero P, Sechi LA, Williams TA, Lenders JWM, Reincke M, Satoh F, et al. Genetics, prevalence, screeningand confirmation of primary aldosteronism: a position statement and consensusof the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020;38(10):1919–28.

    CAS  Article  Google Scholar 

  8. 8.

    Rossi GP, Auchus RJ, Brown M, Lenders JW, Naruse M, Plouin PF, et al. An expert consensus statement on use of adrenal vein sampling for the subtyping of primary aldosteronism. Hypertension. 2014;63(1):151–60.

    CAS  Article  Google Scholar 

  9. 9.

    St-Jean M, Bourdeau I, Martin M, Lacroix A. Aldosterone is aberrantly regulated by various stimuli in a high proportion of patients with primary aldosteronism. J Clin Endocrinol Metab. 2021;106(1):e45–60.

    Article  Google Scholar 

  10. 10.

    El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and other hormones in the regulation of aldosterone production in primary aldosteronism. Front Endocrinol (Lausanne). 2016;7:72.

    Article  Google Scholar 

  11. 11.

    Markou A, Sertedaki A, Kaltsas G, Androulakis II, Marakaki C, Pappa T, et al. Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension. J Clin Endocrinol Metab. 2015;100(8):2857–64.

    CAS  Article  Google Scholar 

  12. 12.

    Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, et al. The unrecognized prevalence of primary aldosteronism: a cross-sectional study. Ann Intern Med. 2020;173(1):10–20.

    Article  Google Scholar 

  13. 13.

    Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40(6):892–6.

    CAS  Article  Google Scholar 

  14. 14.

    Oelkers W, Diederich S, Bahr V. Primary hyperaldosteronism without suppressed renin due to secondary hypertensive kidney damage. J Clin Endocrinol Metab. 2000;85(9):3266–70.

    CAS  Article  Google Scholar 

  15. 15.

    Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Relationships of plasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol. 2007;2(4):722–31.

    CAS  Article  Google Scholar 

  16. 16.

    Zorzi F, Olivieri O, Brazzarola P, Pizzolo F. A late diagnosis of primary aldosteronism. High Blood Press Cardiovasc Prev. 2017;24(3):347–9.

    Article  Google Scholar 

  17. 17.

    Morimoto R, Satani N, Iwakura Y, Ono Y, Kudo M, Nezu M, et al. A case of bilateral aldosterone-producing adenomas differentiated by segmental adrenal venous sampling for bilateral adrenal sparing surgery. J Hum Hypertens. 2016;30(6):379–85.

    CAS  Article  Google Scholar 

  18. 18.

    Watanabe N, Tsunoda K, Sasano H, Omata K, Imai Y, Ito S, et al. Bilateral aldosterone -producing adenomas in two patients diagnosed by immunohistochemical analysis of steroidogenic enzymes. Tohoku J Exp Med. 1996;179(2):123–9.

    CAS  Article  Google Scholar 

  19. 19.

    Chung SD, Huang KH, Yu HJ, Wu KD, Chueh SC. Diagnosis of bilateral ldosterone-producing adenomas. Kidney Int. 2007;72(2):228.

    Article  Google Scholar 

  20. 20.

    Wu VC, Chueh SC, Chang HW, Lin WC, Liu KL, Li HY, et al. Bilateral aldosterone-producing adenomas: differentiation from bilateral adrenal hyperplasia. QJM. 2008;101(1):13–22.

    CAS  Article  Google Scholar 

  21. 21.

    Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51–9.

    Article  Google Scholar 

  22. 22.

    Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension. 2018;72(3):658–66.

    CAS  Article  Google Scholar 

  23. 23.

    Miyake Y, Tanaka K, Nishikawa T, Naruse M, Takayanagi R, Sasano H, et al. Prognosis of primary aldosteronism in Japan: results from a nationwide epidemiological study. Endocr J. 2014;61(1):35–40.

    Article  Google Scholar 

  24. 24.

    Vaidya A, Mulatero P, Baudrand R, Adler GK. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev. 2018;39(6):1057–88.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This study was not funded.

Author information

Affiliations

Authors

Contributions

FL carries out the conception and design of articles and writes papers; LW collects materials, and YD carries out revision and proofreading of the articles. All authors read and approved the final manuscript for publication.

Corresponding author

Correspondence to Yanchun Ding.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the ethics committee of the Second Affiliated Hospital of Dalian Medical University, and the patient gave written consent to participate in the study.

Consent for publication

We obtained informed consent from the patient who allowed to publish the case report.

Competing interests

The authors have no conflicts of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, F., Wang, L. & Ding, Y. A case of primary aldosteronism with a negative aldosterone-to-renin ratio. BMC Cardiovasc Disord 21, 350 (2021). https://doi.org/10.1186/s12872-021-02162-8

Download citation

Keywords

  • Primary aldosteronism
  • Hypertension
  • Adrenal venous sampling